PHIO PHARMACEUTICALS CORP. Deferred Income Tax Expense (Benefit)
PHIO PHARMACEUTICALS CORP. (PHIO) reported Deferred Income Tax Expense (Benefit) of $0 for the 12-month period ending 2018-12-31, per its 10-K filed 2019-03-27.
Discontinued › Cash Flow › Operating Activities
us-gaap:DeferredIncomeTaxExpenseBenefit · last filed 2019-03-27
- PHIO PHARMACEUTICALS CORP. deferred income tax expense (benefit) for the quarter ending 2018-12-31 was $0.00.
- PHIO PHARMACEUTICALS CORP. deferred income tax expense (benefit) for the quarter ending 2018-09-30 was $0.00.
- PHIO PHARMACEUTICALS CORP. deferred income tax expense (benefit) for the quarter ending 2017-12-31 was $0.00.
- PHIO PHARMACEUTICALS CORP. deferred income tax expense (benefit) for the quarter ending 2017-09-30 was $0.00.
- PHIO PHARMACEUTICALS CORP. deferred income tax expense (benefit) for fiscal 2018 was $0.00.
- PHIO PHARMACEUTICALS CORP. deferred income tax expense (benefit) for fiscal 2017 was -$1.62M.
- PHIO PHARMACEUTICALS CORP. deferred income tax expense (benefit) for fiscal 2016 was -$3.63M.
- PHIO PHARMACEUTICALS CORP. deferred income tax expense (benefit) for fiscal 2015 was -$3.96M.
| Period end | Deferred Income Tax Expense (Benefit) 3 month | Deferred Income Tax Expense (Benefit) 6 month | Deferred Income Tax Expense (Benefit) 9 month | Deferred Income Tax Expense (Benefit) 12 month |
|---|---|---|---|---|
| 2018-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2019-03-27 | $0.00 derived: sum of 2 quarters · filed 2019-03-27 | $0.00 10-K · filed 2019-03-27 | |
| 2018-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2018-11-14 | $0.00 10-Q · filed 2018-11-14 | ||
| 2018-06-30 | $0.00 10-Q · filed 2018-08-14 | |||
| 2017-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2019-03-27 | $0.00 derived: sum of 2 quarters · filed 2019-03-27 | $0.00 derived: sum of 3 quarters · filed 2019-03-27 | -$1.62M 10-K · filed 2019-03-27 |
| 2017-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2018-11-14 | $0.00 derived: sum of 2 quarters · filed 2018-11-14 | -$1.62M 10-Q · filed 2018-11-14 | |
| 2017-06-30 | $0.00 derived: 10-Q 6 month − 10-Q 3 month · filed 2018-08-14 | -$1.62M 10-Q · filed 2018-08-14 | ||
| 2017-03-31 | -$1.62M 10-Q · filed 2018-05-10 | |||
| 2016-12-31 | -$3.63M 10-K · filed 2017-03-30 | |||
| 2015-12-31 | -$3.96M 10-K · filed 2017-03-30 | |||
| 2014-12-31 | -$3.31M 10-K · filed 2016-03-30 | |||
| 2013-12-31 | -$11.13M 10-K · filed 2015-03-30 | |||
| 2012-12-31 | -$2.39M 10-K · filed 2014-03-28 | |||
| 2011-12-31 | -$1.11M 10-K · filed 2013-03-29 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| ADIAL PHARMACEUTICALS, INC. (ADIL) | United States | $0.012B | |
| Scienture Holdings, Inc. (SCNX) | United States | $0.012B | -0.38 |
| KIORA PHARMACEUTICALS INC (KPRX) | United States | $0.012B | |
| BIOVIE INC. (BIVI) | United States | $0.012B | |
| Dare Bioscience, Inc. (DARE) | United States | $0.011B | |
| Aspire Biopharma Holdings, Inc. (ASBP) | United States | $0.012B | -0.60 |
| Tempest Therapeutics, Inc. (TPST) | United States | $0.013B | |
| Moleculin Biotech, Inc. (MBRX) | United States | $0.011B | |
| MetaVia Inc. (MTVA) | United States | $0.011B | -0.65 |
| KALA BIO, Inc. (KALA) | United States | $0.011B | -3.33 |